Synthesis, Biological Evaluation, and Binding Mode of a New Class of Oncogenic K-Ras4b Inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• Ras proteins are frequently mutated in life-threatening cancers.
• Developing effective small-molecule inhibitors for mutant Ras proteins has been challenging for decades.
• Recent progress has focused on K-Ras4B binding sites, but inhibitor structural diversity remains limited.

Purpose of the Study:

• To identify novel chemotypes for Ras inhibitors.
• To explore structurally diverse small molecules targeting Ras GDP/GTP-exchange.
• To assess the cellular activity of new inhibitor classes.

Main Methods:

• Synthesis of specific bis(het)aryl ketone derivatives, including hydrazones and oxime ethers.
• Evaluation of these compounds as ligands for Ras binding sites.
• Assessment of cellular activity of the identified inhibitors.

Main Results:

• Hydrazones and oxime ethers of bis(het)aryl ketones represent a new class of Ras inhibitors.
• These compounds exhibit structural variability.
• The identified inhibitors demonstrate significant cellular activity.

Conclusions:

• Bis(het)aryl ketone derivatives offer a promising, structurally diverse approach to developing Ras inhibitors.
• These findings may lead to new therapeutic strategies for Ras-driven cancers.
• Further development of these chemotypes could overcome limitations in current Ras-targeted therapies.